bms-986205
Small moleculeexperimental
Clinical trial activity
22 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
12
Phase 3
4
Phase 4
0
Earliest trial started Feb 18, 2016 (NCT02658890)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 2
- Endometrial Neoplasms · Phase 2
- Glioblastoma · Phase 1
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 1
- Larynx · Phase 2
- Lip · Phase 2
- Lung Neoplasms · Phase 3
- Melanoma · Phase 3
- Neoplasms · Phase 1/Phase 2
- Pharynx · Phase 2
- Skin Neoplasms · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Urinary Bladder Neoplasms · Phase 3
Mechanism of action
- Indoleamine 2,3-dioxygenaseINHIBITOR
IDO1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986205
- bms-986205
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04106414 | Phase 2 | Sep 24, 2019 | Bristol-Myers Squibb, Memorial Sloan-Kettering Cancer Center |
| NCT04047706 | Phase 1 | Sep 1, 2019 | National Cancer Institute (NCI), Northwestern University |
| NCT04007588 | Phase 2 | Jul 31, 2019 | Bristol-Myers Squibb, Harvard University |
| NCT03936374 | Phase 1 | May 8, 2019 | Bristol-Myers Squibb, PPD |
| NCT03854032 | Phase 2 | Apr 9, 2019 | Bristol-Myers Squibb, Thomas Jefferson University |
| NCT03792750 | Phase 1/Phase 2 (Phase 2) | Dec 28, 2018 | Bristol-Myers Squibb |
| NCT03661320 | Phase 3 | Oct 17, 2018 | Bristol-Myers Squibb, Ono Pharmaceuticals |
| NCT03695250 | Phase 1/Phase 2 (Phase 2) | Oct 16, 2018 | Bristol-Myers Squibb, National Cancer Institute (NCI), University of California, Davis |
| NCT03519256 | Phase 2 | May 25, 2018 | Bristol-Myers Squibb |
| NCT03459222 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | Bristol-Myers Squibb |
| NCT03417037 | Phase 3 | May 24, 2018 | Bristol-Myers Squibb |
| NCT03386838 | Phase 3 | Mar 28, 2018 | Bristol-Myers Squibb |
| NCT03335540 | Phase 1 | Mar 13, 2018 | Bristol-Myers Squibb |
| NCT03374228 | Phase 1 | Jan 4, 2018 | Bristol-Myers Squibb |
| NCT03378310 | Phase 1 | Dec 21, 2017 | Bristol-Myers Squibb |
| NCT03346837 | Phase 1 | Nov 22, 2017 | Bristol-Myers Squibb |
| NCT03329846 | Phase 3 | Nov 21, 2017 | Bristol-Myers Squibb |
| NCT03362411 | Phase 1 | Nov 9, 2017 | Bristol-Myers Squibb |
| NCT03312426 | Phase 1 | Oct 9, 2017 | Bristol-Myers Squibb |
| NCT03247283 | Phase 1 | Jul 19, 2017 | Bristol-Myers Squibb |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 21 | 17 | 3 | 2016 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2018 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Ono Pharmaceuticals | For profit | 1 | 0 | 1 | 2018 |
| PPD | For profit | 1 | 0 | 1 | 2019 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2018 |
9 organizations
Page 1 / 1